Major ICMR Study of Indian Healthcare Workers Reveals COVID-19 Vaccine Antibodies Wane within 2 Months for Covaxin & 3 Months for Covishield (AstraZeneca)

In what could be considered problematic implications for COVID-19 vaccination in India, a recent study involving 614 Indian health workers found a "significant" drop in the study participant’s COVID-19-fighting antibodies within a couple of months of the second dose in the case of the COVID-19 vaccine product Covaxin. Of course, more data is needed for a better understanding of these results, but such an outcome may indicate a need for a booster program in the world’s second-most populous nation. Led by the prestigious Indian Council of Medical Research (ICMR)—Regional Medical Research Centre, Bhubaneswar, a state-run research institute and apex trial site organization, the findings don’t necessarily indicate that all vaccinated subjects lose their immune resistance, as memory cells may still be at work suggested Sanghamitra Pati in discussion with Reuters. However, the study findings suggest that those participants that received India’s first “indigenous” vaccine called Covaxin produced significantly less antibodies by the second month after the second jab, while with the Covishield vaccine (Oxford/AstraZeneca), antibodies materially dissipate by month number ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee